Exhibit 10.1  
 AMENDMENT NO. 1  
 Dated as of March 1, 2021  
 to  
 CREDIT AGREEMENT  
 Dated as of June 15, 2018  
 THIS AMENDMENT NO. 1 (this “Amendment”) is made as of March 1, 2021 by and among HAEMONETICS CORPORATION, a Massachusetts corporation (the “Company”), the financial institutions listed on the signature pages hereof as “Term A-2 Lenders”, the existing Lenders (immediately prior to the effectiveness of this Amendment) party hereto (the “Existing Lenders”), the Issuing Banks, the Swingline Lender and JPMORGAN CHASE BANK, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement, dated as of June 15, 2018, by and among the Company, the Lenders and the Administrative Agent (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”; the Credit Agreement as amended by this Amendment, the “Amended Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Amended Credit Agreement.  
 WHEREAS, the Company has requested that (i) the Term A-2 Lenders agree to provide a tranche of Incremental Term Loans pursuant to Section 2.21 of the Credit Agreement in an aggregate original principal amount of $150,000,000 and (ii) the Existing Lenders, the Issuing Banks, the Swingline Lender and the Administrative Agent agree to make certain other amendments to the ; and